Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis | Zendy

G. T. Siwek | Zendy; Kirsty Dodgson | Zendy; M.-S. de Margarida | Zendy; Luther A. Bartelt | Zendy; S. B. Kilborn | Zendy; Peter Hoth | Zendy; Daniel J. Diekema | Zendy; Michael A. Pfaller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis

Author(s) -

G. T. Siwek,

Kirsty Dodgson,

M.-S. de Margarida,

Luther A. Bartelt,

S. B. Kilborn,

Peter Hoth,

Daniel J. Diekema,

Michael A. Pfaller

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/422723

Subject(s) - voriconazole , zygomycosis , medicine , hematopoietic stem cell transplantation , antifungal , hematopoietic stem cell , population , surgery , transplantation , stem cell , amphotericin b , haematopoiesis , dermatology , environmental health , biology , genetics

We report 4 cases of invasive zygomycosis in hematopoietic stem cell transplant recipients, all occurring after May 2003, when voriconazole began to be used as antifungal prophylaxis. No cases of zygomycosis had been detected in this population in the 3 years prior to May 2003. All 4 patients were receiving immunosuppressive therapy for presumed graft-versus-host disease. Profoundly immunosuppressed patients receiving voriconazole prophylaxis remain at risk for less-common pathogens that are intrinsically resistant to this agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research